#310 Medications for Heart Failure with Preserved or Mildly-Reduced Ejection Fraction: Heart Failure or Heart Success?
CLINICAL QUESTION
Which medications reduce death or hospitalization in patients with heart failure (HF) with preserved or mildly-reduced ejection fraction (EF >40%)?
BOTTOM LINE
In patients with HF with EF >40%, only mineralocorticoid receptor antagonists (MRA) and sodium-glucose cotransporter 2 inhibitors (SGLT2i) reduce HF hospitalizations, and nothing has been shown to reduce death. Compared to placebo, one patient avoids HF hospitalization for every 41 receiving an MRA for ~3 years, or for every 32 receiving an SGLT2i for ~2 years.
Reading Tools for Practice Article can earn you MainPro+ Credits
Join NowAlready a CFPCLearn Member? Log in
EVIDENCE
- Five systematic reviews in last 5 years assessed medications in HF with EF >40%.1-5 Focusing on the most complete (results statistically significant unless otherwise stated):
- MRAs [13 randomized controlled trials (RCTs), 4459 patients, follow-up ~3 years]:1
- HF hospitalization: 11.2% versus 13.6% (placebo), number needed to treat (NNT)=41.
- Hyperkalemia (≥5.5mmol/L): 17.5% versus 8.3% (placebo), number needed to harm (NNH)=11.
- SGLT2i:
- Meta-analysis (5 RCTs, 9726 patients):5 29% relative risk reduction in HF hospitalization with SGLT2i versus placebo, regardless of diabetes
- EMPEROR-Preserved:6 Largest blinded RCT (industry-funded): Empagliflozin 10mg/day versus placebo for 2.2 years (5988 patients, age 72, 55% male)
- HF hospitalization: 8.6% versus 11.8% (placebo), NNT=32.
- Adverse events: Hypotension (not defined) [6.6% versus 5.2% (placebo), NNH=56], urinary tract infections [9.9% versus 8.1% (placebo), NNH=56], and genital infections [2.2% versus 0.7% (placebo), NNH=67].
- EMPEROR-Preserved:6 Largest blinded RCT (industry-funded): Empagliflozin 10mg/day versus placebo for 2.2 years (5988 patients, age 72, 55% male)
- Meta-analysis (5 RCTs, 9726 patients):5 29% relative risk reduction in HF hospitalization with SGLT2i versus placebo, regardless of diabetes
- MRAs [13 randomized controlled trials (RCTs), 4459 patients, follow-up ~3 years]:1
- Medications that do not reduce hospitalizations or deaths:1
- ACE inhibitors (8 RCTs, 2061 patients)
- Angiotensin-receptor blockers (ARBs) (8 RCTs, 8755 patients)
- Beta-blockers (10 RCTs, 3087 patients)
- Sacubitril-valsartan (3 RCTs, 7702 patients)
- Original meta-analysis erroneously suggested reduced hospitalizations. When re-analyzed, no benefit found.7
- No RCTs of clinical outcomes for loop diuretics in HF.8,9
- No medication reduces mortality.1-6
- “HF with preserved EF”:
- Means EF ≥50%.10
- Many trials include patients with EF 41-49% (now called mildly-reduced ejection fraction10).1-6
- ~50% of patients with HF have an EF >40%.11
- Guidelines (published before EMPEROR-Preserved) recommend treating hypertension and using loop diuretics for fluid overload,12-14 ± MRA and/or candesartan (based on limited evidence and options at the time of writing).12
- Costs: Spironolactone 25mg $140/year, empagliflozin splitting 25mg in half=12.5mg (trial dose=10 mg) $560/year.15
Latest Tools for Practice
#377 How to slow the flow IV: Combined oral contraceptives
In premenopausal heavy menstrual bleeding due to benign etiology, do combined oral contraceptives (COC) improve patient outcomes?
#376 Testosterone supplementation for cis-gender men: Let’s (andro-)pause for a moment (Update)
What are the benefits and harms of testosterone supplementation in healthy cis-gender men or those with age-related low testosterone?
#375 Pharm for Fibro: Can antidepressants ease the pain?
Do antidepressants reduce pain in patients with fibromyalgia?
How fortunate that the FDA requires the cvs studies that indirectly resulted in discovering these benefits of SLG2Is from their studies for DM2 .They are very expensive but likely will have a net benefit